Roland B. Walter
M.S., University of Washington, Epidemiology (Clinical Research), 2011.
Ph.D., University of Washington, Experimental Pathology, 2006.
M.D., University of Zurich, Medicine, 1997.
Dr. Walter's laboratory research is focused on human acute myeloid leukemia (AML), in particular on the delineation of the clonal origin of AML, the molecular and phenotypic characterization of AML stem and progenitor cells, and the interaction between AML cells in their environment. A long-term goal of his preclinical studies is the development of novel therapeutic strategies aimed to eradicate AML stem and progenitor cells. Findings from such studies are then translated into the clinic and tested in early phase human trials.
A second research interest of Dr. Walter is the development and conduct of clinical trials in AML. Dr. Walter is currently the Principal Investigator of several early phase clinical trials that test new drugs and drug combinations in AML; he also leads a phase 2 study that explores a strategy of outpatient management of selected AML/MDS patients following intensive induction chemotherapy.
(Reading, Writing, Speaking)
English: (Fluent, Fluent, Fluent)
German: (Fluent, Fluent, Fluent)
Schwyzerdutsch: (Fluent, Fluent, Fluent)
American Society of Hematology
Honors and Awards
2009-2012, Mentored Patient-Oriented Research Career Development Award (K23), National Cancer Institute, National Institutes of Health (NIH), National Institute of Health (NIH)
2006-2009, Special Fellow Career Development Award, Leukemia & Lymphoma Society
2005, SIAK/ESSEX Award in Applied Cancer Research Switzerland
2005, Dr. Ernst Th. Jucker Price for Cancer Research Switzerland
2005-2007, Clinical/Translational Research Scholar Award, American Society of Hematology
2005-2005, Career Development Award, Janggen-Pohn Foundation, Switzerland
2004-2004, Interdisciplinary Dual Mentor Fellowship, Fred Hutchinson Cancer Research Center
2002-2004, Fellowship for Advanced Researchers, Swiss Foundation for Medical-Biological Grants
2008-2010, Research Associate, Fred Hutchinson Cancer Research Center, Clinical Research Division
2008-2010, Acting Instructor in Medicine, University of Washington, Department of Medicine, Division of Hematology
2005-2007, Fellow, University of Washington, Department of Medicine, Division of Hematology
2002-2008, Post-Doctoral Research Fellow, Fred Hutchinson Cancer Research Center, Clinical Research Division
1999-2002, Resident, University of Zurich, Department of Medicine
1997-1999, Resident, Kantonsspital Chur, Department of Medicine
1996-1997, Research Fellow, University of Zurich, Department of Medicine
Comparative analysis of flow cytometry and morphology for the detection of acute myeloid leukaemia cells in cerebrospinal fluid.. British journal of haematology.. 2015.
How Do Pre-Transplant Peripheral Blood Counts Inform Us About Post-Transplant Outcomes in Acute Myeloid Leukemia? Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2015.
Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.. Clinical cancer research : an official journal of the American Association for Cancer Research.. 2015.
Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 21(3):559-64.. 2015.
Minimal residual disease in acute myeloid leukemia-current status and future perspectives.. Current hematologic malignancy reports. 10(2):132-44.. 2015.
Minimal residual disease-directed therapy in acute myeloid leukemia.. Blood. 125(15):2331-2335.. 2015.
Update on Antigen-Specific Immunotherapy of Acute Myeloid Leukemia.. Current hematologic malignancy reports.. 2015.
Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(11):1258-64.. 2015.
G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.. American journal of hematology. 90(4):295-300.. 2015.
Factors associated with early re-induction chemotherapy for adults with acute myeloid leukemia.. Leukemia & lymphoma. :1-10.. 2014.
Non-steroidal Anti-inflammatory Drugs and Cancer Risk in Women: Results from the Women's Health Initiative.. International journal of cancer. Journal international du cancer.. 2014.
Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia.. Expert review of hematology.. 2014.
Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myeloid Leukemia.. Clinical cancer research : an official journal of the American Association for Cancer Research.. 2014.